Prolonged dual antiplatelet therapy strategy in acute coronary syndrome patients post-standard therapy and adverse event-free: An analysis based on OPT-CAD risk score stratification
Xiaolin Su , Miaohan Qiu , Haiwei Liu , Kai Xu , Xiaozeng Wang , Jing Li , Yi Li , Yaling Han
{"title":"Prolonged dual antiplatelet therapy strategy in acute coronary syndrome patients post-standard therapy and adverse event-free: An analysis based on OPT-CAD risk score stratification","authors":"Xiaolin Su , Miaohan Qiu , Haiwei Liu , Kai Xu , Xiaozeng Wang , Jing Li , Yi Li , Yaling Han","doi":"10.1016/j.ijcard.2025.133636","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>The optimal antiplatelet strategy for patients with acute coronary syndrome (ACS) after the standard 12-month dual antiplatelet therapy (DAPT) is still a matter of concern. We aimed to apply the OPT-CAD score for risk stratification and to identify those who would derive benefit from prolonged DAPT beyond 12 months.</div></div><div><h3>Methods</h3><div>In this post hoc analysis of OPT-CAD study, 7154 patients with ACS, who completed 12-month DAPT without any adverse events, were divided into low-risk (<em>n</em> = 4171) and medium-to-high-risk (<em>n</em> = 2983) groups based on the OPT-CAD risk score. The primary endpoint was ischemic events, defined as the composite of cardiac death, myocardial infarction (MI) or stroke occurring between 12 and 24 months. The secondary endpoints included all-cause death and Bleeding Academic Research Consortium (BARC) type 3 or 5 bleeding.</div></div><div><h3>Results</h3><div>After propensity score matching, in low-risk patients, ischemic events, all-cause death and BARC type 3 or 5 bleeding were comparable between prolonged DAPT and single antiplatelet therapy (SAPT) regimens. However, among the medium-to-high-risk patients, prolonged DAPT was associated with a reduction in ischemic events (hazard ratio [HR] 0.48, 95 % confidence intervals [CI] 0.29–0.81, <em>P</em> = 0.0062) and all-cause death (HR 0.44, 95 %CI 0.21–0.89, <em>P</em> = 0.0220) without apparently increasing the risk of BARC type 3 or 5 bleeding (HR 1.49, 95 %CI 0.25–8.92, <em>P</em> = 0.6622).</div></div><div><h3>Conclusions</h3><div>The OPT-CAD risk score demonstrated moderate ability to predict long-term ischemic events and all-cause mortality in patients with ACS who completed the standard 12-month DAPT without adverse events, and might help identify those more likely to derive benefit from prolonged DAPT.</div></div>","PeriodicalId":13710,"journal":{"name":"International journal of cardiology","volume":"439 ","pages":"Article 133636"},"PeriodicalIF":3.2000,"publicationDate":"2025-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International journal of cardiology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0167527325006795","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
Abstract
Background
The optimal antiplatelet strategy for patients with acute coronary syndrome (ACS) after the standard 12-month dual antiplatelet therapy (DAPT) is still a matter of concern. We aimed to apply the OPT-CAD score for risk stratification and to identify those who would derive benefit from prolonged DAPT beyond 12 months.
Methods
In this post hoc analysis of OPT-CAD study, 7154 patients with ACS, who completed 12-month DAPT without any adverse events, were divided into low-risk (n = 4171) and medium-to-high-risk (n = 2983) groups based on the OPT-CAD risk score. The primary endpoint was ischemic events, defined as the composite of cardiac death, myocardial infarction (MI) or stroke occurring between 12 and 24 months. The secondary endpoints included all-cause death and Bleeding Academic Research Consortium (BARC) type 3 or 5 bleeding.
Results
After propensity score matching, in low-risk patients, ischemic events, all-cause death and BARC type 3 or 5 bleeding were comparable between prolonged DAPT and single antiplatelet therapy (SAPT) regimens. However, among the medium-to-high-risk patients, prolonged DAPT was associated with a reduction in ischemic events (hazard ratio [HR] 0.48, 95 % confidence intervals [CI] 0.29–0.81, P = 0.0062) and all-cause death (HR 0.44, 95 %CI 0.21–0.89, P = 0.0220) without apparently increasing the risk of BARC type 3 or 5 bleeding (HR 1.49, 95 %CI 0.25–8.92, P = 0.6622).
Conclusions
The OPT-CAD risk score demonstrated moderate ability to predict long-term ischemic events and all-cause mortality in patients with ACS who completed the standard 12-month DAPT without adverse events, and might help identify those more likely to derive benefit from prolonged DAPT.
期刊介绍:
The International Journal of Cardiology is devoted to cardiology in the broadest sense. Both basic research and clinical papers can be submitted. The journal serves the interest of both practicing clinicians and researchers.
In addition to original papers, we are launching a range of new manuscript types, including Consensus and Position Papers, Systematic Reviews, Meta-analyses, and Short communications. Case reports are no longer acceptable. Controversial techniques, issues on health policy and social medicine are discussed and serve as useful tools for encouraging debate.